EurekAlert!

Study explores whether dietary supplement could provide first effective treatment for cirrhosis

A dietary supplement used to build muscle – or prevent muscle loss as a result of ageing or illness – is to be trialled as a potential treatment for chronic liver disease. Β-hydroxy β-methylbutyrate, ...
Los Angeles Times

Muscle drink with HMB targets the middle-aged

A new muscle drink on the market isn’t for bodybuilders or workout fanatics: It’s aimed at middle-aged and older adults who are losing muscle naturally because of age. Ensure Muscle Health promises ...
WKRN-TV

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

HMB-001 is a novel bispecific antibody designed to be the first prophylactic treatment for Glanzmann Thrombasthenia (GT) and other debilitating bleeding disorders Phase 1 was successfully completed in ...
WGNO

Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB ...

In second oral presentation, Hemab presented first preclinical data for HMB-002, a potential novel treatment for Von Willebrand Disease Results from lived experience of Glanzmann thrombasthenia (GT360 ...
Fox2Now St. Louis

Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia

CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41 st Annual JP Morgan Healthcare Conference "HMB-001 is the first candidate of our emerging pipeline to ...